Literature DB >> 15985713

Neuroprotective potential of three neuropeptides PACAP, VIP and PHI.

Agnieszka Dejda1, Paulina Sokołowska, Jerzy Z Nowak.   

Abstract

Pituitary adenylate cyclase activating polypeptide (PACAP), vasoactive intestinal peptide (VIP) and peptide histidine-isoleucine (PHI), are structurally related endogenous peptides widely expressed in the central and peripheral nervous system and showing rich profile of biological activities. They act as neurotransmitters, neuromodulators and neurotrophic factors. Recently, their neuroprotective potential has been revealed in numerous in vitro and in vivo models. Thus, PACAP and VIP protected the cells from neurotoxic effects of ethanol, hydrogen peroxide (H2O2, beta-amyloid and glycoprotein 120 (gp120). Moreover, PACAP showed neuroprotection against glutamate, human prion protein fragment 106-126 [PrP(106-126)] and C2-ceramide. Both peptides reduced brain damage after ischemia and ameliorated neurological deficits in a model of Parkinson's disease. Neuroprotective potential of PHI has not been thoroughly investigated yet, but several results obtained in the last years do not exclude it. The mechanism underlying neuroprotective properties of PACAP seems to involve activation of adenylyl cyclase (AC) --> cyclic adenosine 3',5'-mono-phosphate (cAMP) --> protein kinase A (PKA) and mitogen-activated protein (MAP) kinase pathways, and inhibition of caspase-3. PACAP can also, yet indirectly, stimulate astrocytes to release neuroprotective factors, such as regulated upon activation normal T cell expressed and secreted (RANTES) and macrophage inflammatory protein 1 (MIP-1) chemokines. Neuroprotective activity of VIP seems to involve an indirect mechanism requiring astrocytes. VIP-stimulated astrocytes secrete neuroprotective proteins, including activity-dependent neurotrophic factor (ADNF) and activity-dependent neuroprotective protein (ADNP), as well as a number of cytokines. However, in the activated microglia, VIP and PACAP are capable of inhibiting the production of inflammatory mediators which can lead to neurodegenerative processes within the brain. In conclusion, studies carried out on the central nervous system have shown that PACAP, VIP, and likely PHI, are endowed with a neuroprotective potential, which renders them (or their derivatives) promising therapeutic agents in several psychoneurological disorders linked to neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15985713

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  59 in total

1.  Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells.

Authors:  Yazhou Li; David Tweedie; Mark P Mattson; Harold W Holloway; Nigel H Greig
Journal:  J Neurochem       Date:  2010-04-02       Impact factor: 5.372

Review 2.  VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Authors:  Alain Couvineau; Marc Laburthe
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Expanding the dipeptidyl peptidase 4-regulated peptidome via an optimized peptidomics platform.

Authors:  Arthur D Tinoco; Debarati M Tagore; Alan Saghatelian
Journal:  J Am Chem Soc       Date:  2010-03-24       Impact factor: 15.419

4.  Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.

Authors:  Elena Gonzalez-Rey; Amelia Fernandez-Martin; Alejo Chorny; Javier Martin; David Pozo; Doina Ganea; Mario Delgado
Journal:  Am J Pathol       Date:  2006-04       Impact factor: 4.307

5.  RANTES release contributes to the protective action of PACAP38 against sodium nitroprusside in cortical neurons.

Authors:  Alma Sanchez; Debjani Tripathy; Paula Grammas
Journal:  Neuropeptides       Date:  2009-06-03       Impact factor: 3.286

6.  RANTES upregulation in the Alzheimer's disease brain: a possible neuroprotective role.

Authors:  Debjani Tripathy; Lakshmi Thirumangalakudi; Paula Grammas
Journal:  Neurobiol Aging       Date:  2008-04-28       Impact factor: 4.673

7.  Biological and structural analysis of truncated analogs of PACAP27.

Authors:  Steve Bourgault; David Vaudry; Laure Guilhaudis; Emilie Raoult; Alain Couvineau; Marc Laburthe; Isabelle Ségalas-Milazzo; Hubert Vaudry; Alain Fournier
Journal:  J Mol Neurosci       Date:  2008-05-13       Impact factor: 3.444

8.  PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease.

Authors:  Dwayne Brown; Andrea Tamas; Dora Reglödi; Yousef Tizabi
Journal:  J Mol Neurosci       Date:  2013-04-28       Impact factor: 3.444

9.  Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates proliferation of reactive astrocytes in vitro.

Authors:  Tomoya Nakamachi; Keisuke Nakamura; Kanako Oshida; Nobuyuki Kagami; Hiroyoshi Mori; Jun Watanabe; Satoru Arata; Sachiko Yofu; Kimi Endo; Yoshihiro Wada; Motohide Hori; Daisuke Tsuchikawa; Makoto Kato; Seiji Shioda
Journal:  J Mol Neurosci       Date:  2010-06-24       Impact factor: 3.444

10.  Vasoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission.

Authors:  Kai Yang; Catherine H Trepanier; Hongbin Li; Michael A Beazely; Ethan A Lerner; Michael F Jackson; John F MacDonald
Journal:  Hippocampus       Date:  2009-09       Impact factor: 3.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.